ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,08165
0,00%
Bitcoin
69.393,02
0,09%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Enliven Therapeutics Inc (ELVN)

  7. Enliven Therapeutics Inc (ELVN) News

ELVN

Enliven Therapeutics (ELVN)

Enliven Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ELVN
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
30/05/202423h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
30/05/202423h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422h06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422h05GlobeNewswire Inc.Enliven Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:ELVNEnliven Therapeutics Inc
28/05/202423h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
28/05/202423h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
17/05/202401h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422h05GlobeNewswire Inc.Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
14/05/202401h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
09/05/202402h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
08/05/202400h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
11/04/202413h55GlobeNewswire Inc.Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaNASDAQ:ELVNEnliven Therapeutics Inc
09/04/202422h05GlobeNewswire Inc.Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of DirectorsNASDAQ:ELVNEnliven Therapeutics Inc
28/03/202421h05GlobeNewswire Inc.Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024NASDAQ:ELVNEnliven Therapeutics Inc
19/03/202413h30GlobeNewswire Inc.Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline UpdatesNASDAQ:ELVNEnliven Therapeutics Inc
14/03/202421h05GlobeNewswire Inc.Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
09/03/202401h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
06/03/202423h43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
04/03/202423h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
29/02/202423h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
27/02/202422h05GlobeNewswire Inc.Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:ELVNEnliven Therapeutics Inc
27/02/202422h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
21/02/202401h35Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
21/02/202401h27Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
21/02/202401h24Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
16/02/202422h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELVN

Kürzlich von Ihnen besucht

OKEX
HMCETH
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten